MITA Thanks Senators and Representatives for Bipartisan Efforts to Secure Medicare Coverage of Low-Dose CT Imaging for Lung Cancer Detection


Washington, D.C. – The Medical Imaging & Technology Alliance (MITA) today thanked Senators Diane Feinstein (D-Calif.) and Johnny Isakson (R-Ga.), as well as Representatives Charles Boustany (R-La.), John Barrow (D-Ga.), Jim Renacci (R-Ohio) and Richard Neal (D-Mass.), for leading bipartisan letters urging the Centers for Medicare & Medicaid Services (CMS) to complete a National Coverage Determination (NCD) for low-dose computed tomography (LDCT) for Medicare beneficiaries with a high risk of developing lung cancer.

“We commend the authors of these bipartisan letters for their leadership and commitment to providing care for the tens of thousands of seniors who stand to benefit from access to LDCT to detect lung cancer at its earliest, most treatable stage,” said Gail Rodriguez, executive director of MITA. “This year alone, an estimated 159,260 people are expected to die from this disease, but the devastating death toll could be reduced by 20 percent if CMS provides Medicare beneficiaries with the same access to life-saving low-dose imaging technologies that many individuals with private health insurance already enjoy.”

The Senate letter spearheaded by Sens. Feinstein and Isakson was signed by 45 Senators, while the House letter authored by Reps. Boustany, Renacci, Barrow and Neal garnered 133 signatures.

One reason lung cancer is so deadly is that symptoms of the disease do not typically manifest until it has reached advanced stages. In approximately 40 percent of those diagnosed with lung cancer, the diagnosis is made after the disease has progressed. Additionally, because the median age of lung cancer diagnosis is age 70, it is essential that Medicare beneficiaries have access to this diagnostic tool.

LDCT is already covered by the Department of Veterans Affairs (VA), the Department of Energy (DoE) and a number of private insurers, such as WellPoint, Blue Cross Blue Shield affiliates and Anthem affiliates. Several patient advocate organizations and medical professional societies across the country have also voiced strong support for coverage, including the American Association for Thoracic Surgery (AATS), the American Cancer Society (ACS), the American College of Radiology (ACR), the American Society of Clinical Oncology (ASCO) and the Lung Cancer Alliance (LCA).

In January, the United States Preventive Services Task Force (USPSTF) finalized its recommendation for the use of annual LDCT scans for individuals 55 to 80 years of age who are at high risk for lung cancer.


The Medical Imaging & Technology Alliance (MITA), a division of NEMA, is the collective voice of medical imaging equipment, radiation therapy and radiopharmaceutical manufacturers, innovators and product developers. It represents companies whose sales comprise more than 90 percent of the global market for medical imaging and radiation therapy technologies. For more information, visit Follow MITA on Twitter @MITAToday.